Madrigal Pharmaceuticals: Rezdiffra Efficacy Data Published in Journal of Hepatology

Madrigal Pharmaceuticals announced the publication of a pre-specified secondary analysis from a clinical trial demonstrating consistent efficacy of Rezdiffra across common genetic risk variants for metabolic dysfunction-associated steatohepatitis (MASH).